AR076437A1 - Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal - Google Patents

Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal

Info

Publication number
AR076437A1
AR076437A1 ARP090103175A ARP090103175A AR076437A1 AR 076437 A1 AR076437 A1 AR 076437A1 AR P090103175 A ARP090103175 A AR P090103175A AR P090103175 A ARP090103175 A AR P090103175A AR 076437 A1 AR076437 A1 AR 076437A1
Authority
AR
Argentina
Prior art keywords
immune response
cause
antigen
immunological composition
animal
Prior art date
Application number
ARP090103175A
Other languages
English (en)
Inventor
Zhixian Xin
William John Cheshire
Philip Ralph Lehrbach
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008904261A external-priority patent/AU2008904261A0/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR076437A1 publication Critical patent/AR076437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones inmunologicas aplicables al virus de fiebre efímera bovina (BEFV), el herpesvirus bovino 1 (IBR) o el virus de la fiebre catarral (BTV), y que comprenden sulfalipo-ciclodextrina (SL-CD), saponina o Quil A y, opcionalmente, por lo menos un antígeno, que puede ser un antígeno veterinario, el cual puede ser un antígeno bovino, para provocar una respuesta inmune contra BEFV, IBR o BTV en un animal al cual se le administra la composicion. En particular, la respuesta inmune es protectora. El método de preparacion de la composicion inmunologica comprende agregar Quil A a un virus. Reivindicacion 3: La composicion inmunologica de la reivindicacion 2 caracterizada porque por lo menos un antígeno se selecciona de bacterias, virus, péptidos, polipéptidos, ácidos nucleicos, o una combinacion de los mismos. Reivindicacion 13: Una composicion inmunologica preparada al combinar Quil A y por lo menos un antígeno vírico antes de agregar por lo menos un adyuvante adicional. Reivindicacion 15: La composicion inmunologica preparada como en la reivindicacion 14, caracterizada porque el por lo menos un adyuvante adicional se selecciona de SL-CD, hidroxido de aluminio, aceite SP o carbopol.
ARP090103175A 2008-08-19 2009-08-19 Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal AR076437A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008904261A AU2008904261A0 (en) 2008-08-19 Immunological Composition
US9209108P 2008-08-27 2008-08-27

Publications (1)

Publication Number Publication Date
AR076437A1 true AR076437A1 (es) 2011-06-15

Family

ID=41696586

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103175A AR076437A1 (es) 2008-08-19 2009-08-19 Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal

Country Status (17)

Country Link
US (1) US20100047279A1 (es)
EP (1) EP2331126A1 (es)
JP (1) JP2012500282A (es)
KR (1) KR101320141B1 (es)
CN (1) CN102186502B (es)
AR (1) AR076437A1 (es)
AU (1) AU2009282581B2 (es)
BR (1) BRPI0917290A8 (es)
CA (1) CA2734654C (es)
CO (1) CO6341568A2 (es)
HK (1) HK1157182A1 (es)
MX (1) MX2011001910A (es)
RU (1) RU2506094C2 (es)
TW (1) TW201010719A (es)
UA (1) UA101385C2 (es)
WO (1) WO2010022135A1 (es)
ZA (1) ZA201102082B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011043962A2 (en) * 2009-10-07 2011-04-14 Wyeth Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
EP2944322B1 (en) * 2010-03-12 2018-01-17 Merial, Inc Bluetongue virus recombinant vaccines and uses thereof
US20140086961A1 (en) * 2011-05-09 2014-03-27 Universitat Autonoma De Barcelona Use of cyclodextrins in diets, water or vaccine adjuvants to boost the immune system of fish
CN103083658B (zh) * 2011-10-27 2015-09-02 普莱柯生物工程股份有限公司 一种用于治疗或预防猪感染性疾病的疫苗佐剂组合物
US20160256540A1 (en) 2013-10-17 2016-09-08 Zoetis Services Llc Methods And Compositions For Treatment Of S. Equi Infection
BR112016027335B1 (pt) * 2014-05-23 2021-06-08 Phibro-Animal Health Corporation combinação, uso desta, método para produzir a referida combinação e composição formulada para administração a um animal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295749A1 (en) * 1987-06-15 1988-12-21 Duphar International Research B.V Sulpholipopolysaccharides as stimulators of the non-specific defence mechanism
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP1009429B1 (en) * 1997-08-29 2009-07-08 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
AU773204C (en) * 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
EP1104767A1 (en) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN1909925B (zh) * 2004-02-20 2010-10-13 中国农业大学 一种免疫佐剂
JP2008502605A (ja) * 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
RU2288007C2 (ru) * 2005-02-17 2006-11-27 ГНУ ВНИИ ветеринарной вирусологии и микробиологии Способ изготовления ассоциированной инактивированной культуральной вакцины против инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота

Also Published As

Publication number Publication date
TW201010719A (en) 2010-03-16
AU2009282581B2 (en) 2013-12-19
JP2012500282A (ja) 2012-01-05
MX2011001910A (es) 2011-06-20
UA101385C2 (ru) 2013-03-25
CO6341568A2 (es) 2011-11-21
RU2506094C2 (ru) 2014-02-10
KR101320141B1 (ko) 2013-11-13
HK1157182A1 (en) 2012-06-29
WO2010022135A1 (en) 2010-02-25
CN102186502A (zh) 2011-09-14
ZA201102082B (en) 2011-11-30
KR20110044791A (ko) 2011-04-29
EP2331126A1 (en) 2011-06-15
AU2009282581A1 (en) 2010-02-25
CA2734654C (en) 2015-02-10
BRPI0917290A8 (pt) 2016-11-01
BRPI0917290A2 (pt) 2015-11-10
US20100047279A1 (en) 2010-02-25
RU2011105863A (ru) 2012-09-27
CA2734654A1 (en) 2010-02-25
CN102186502B (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
AR076437A1 (es) Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
ME01199B (me) Nove kompozicije adjuvanta
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
PE20061287A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
AR061894A1 (es) Vacunas para malaria
MX2009006178A (es) Vacuna contra salmonela.
EA201892735A1 (ru) Состав вакцины против hiv
MY143347A (en) Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
CU23759A3 (es) Composiciones inmunogénicas
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
AR103427A1 (es) Vacuna contra la fiebre aftosa
CL2011000922A1 (es) Composicion de vacuna que comprende un vector de expresion canarypox capaz de expresar en un equino proteinas virales del virus de la peste equina africana (ahsv) vp2 y vp5; y su uso para inducir una respuesta inmune protectora contra la peste equina africana en un animal equino.
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal